Vitamin D deficiency in human and murine sepsis by Parekh, Dhruv et al.
Copyright © 2016 by the Society of Critical Care Medicine and Wolters Kluwer Health, Inc. All Rights Reserved.Copyright © 2016 by the Society of Critical Care Medicine and Wolters Kluwer Health, Inc. All Rights Reserved.
282 www.ccmjournal.org	 February	2017	•	Volume	45	•	Number	2
Objectives:	 	Vitamin	D	deficiency	has	been	 implicated	as	a	patho-
genic	factor	in	sepsis	and	ICU	mortality	but	causality	of	these	associ-
ations	has	not	been	demonstrated.	To	determine	whether	sepsis	and	
severe	sepsis	are	associated	with	vitamin	D	deficiency	and	to	deter-
mine	whether	vitamin	D	deficiency	influences	the	severity	of	sepsis.
Design, Setting, and Patients:	Sixty-one	patients	with	sepsis	and	
severe	sepsis	from	two	large	U.K.	hospitals	and	20	healthy	con-
trols	were	recruited.	Murine	models	of	cecal	ligation	and	puncture	
and	 intratracheal	 lipopolysaccharide	were	 undertaken	 in	 normal	
and	vitamin	D	deficient	mice	to	address	the	issue	of	causality.
Measurements and Main Results:	Patients	with	severe	sepsis	had	sig-
nificantly	lower	concentrations	of	25-hydroxyvitamin	D3	than	patients	
with	either	mild	sepsis	or	age-matched	healthy	controls	(15.7	vs	49.5	
vs	66.5	nmol/L;	p	=	0.0001).	25-hydroxyvitamin	D3	concentrations	
were	significantly	 lower	 in	patients	who	had	positive	microbiologic	
culture	than	those	who	were	culture	negative	(p	=	0.0023)	as	well	
as	those	who	died	within	30	days	of	hospital	admission	(p	=	0.025).	
Vitamin	D	deficiency	in	murine	sepsis	was	associated	with	increased	
peritoneal	(p	=	0.037),	systemic	(p	=	0.019),	and	bronchoalveolar	
lavage	(p	=	0.011)	quantitative	bacterial	culture.	This	was	associated	
with	reduced	local	expression	of	the	cathelicidin-related	antimicrobial	
peptide	as	well	 as	evidence	of	defective	macrophage	phagocyto-
sis	(p	=	0.029).	In	the	intratracheal	lipopolysaccharide	model,	1,500	
IU	 of	 intraperitoneal	 cholecalciferol	 treatment	 6	 hours	 postinjury	
reduced	alveolar	inflammation,	cellular	damage,	and	hypoxia.
Conclusions:	 Vitamin	D	deficiency	 is	 common	 in	 severe	 sepsis.	
This	appears	to	contribute	to	the	development	of	the	condition	in	
clinically	relevant	murine	models	and	approaches	to	correct	vita-
min	D	 deficiency	 in	 patients	 with	 sepsis	 should	 be	 developed.	
(Crit Care Med	2017;	45:282–289)
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Sepsis remains a common cause for hospital admission and is the commonest reason for admission to ICUs. Despite improvements in management of sepsis, the prevalence of 
sepsis continues to increase and is the leading cause of death in 
critically ill patients, affecting approximately 750,000 U.S. patients 
annually with a mortality rate of approximately 25% (1, 2).
Sepsis describes a complex clinical syndrome that results 
from a harmful or damaging host response to infection. A sig-
nificant proportion of patients with sepsis go on to develop 
severe sepsis or septic shock (1, 2). Despite considerable 
research, there still remains a lack of targeted pharmacologic 
interventions to treat and improve outcomes from sepsis (3, 4).
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Over 1 billion people worldwide are believed to have  vitamin D 
deficiency (VDD) (5). Epidemiologic studies have demonstrated 
that 25-hydroxyvitamin D
3
 (25[OH]D
3
) concentrations are 
related to geography and season (6, 7). In a study of middle-aged 
adults in the United Kingdom, 40% had serum 25(OH)D
3
 con-
centrations above 30 ng/L (75 nmol/L) in the summer months 
but this decreased to less than 17% in the winter (8). The preva-
lence and mortality of sepsis is higher during the winter when 
25(OH)D
3
 concentrations are lower (9).
Vitamin D metabolites have important pleiotropic effects on 
human immunity, acting as modulators of cells of the innate and 
adaptive system (10). Biologically active 1,25(OH)
2
D
3
 directly 
enhances signaling to increase antimicrobial peptides, cathelicidin 
(LL-37, its active form), and β-defensin by the innate immune 
system (11). Gram-positive bacteria, invasive pneumococcal dis-
ease, meningococcal disease, and group A streptococcal disease 
are more common when 25(OH)D
3
 concentrations are low (12).
VDD is associated with an increased risk of ICU admission 
and mortality in patients with pneumonia (13). Studies sug-
gest VDD is common in critically ill patients and associated 
with adverse outcome (14, 15). Patients with sepsis who are not 
vitamin D sufficient (VDS) have an increased risk of mortality 
after critical care initiation (16). Recent meta-analyses support 
the association of VDD with increased susceptibility for severe 
infection, sepsis, and mortality in the critically ill (17, 18).
We believe that VDD is a determinant of the severity of 
sepsis because of effects on the host defense against infec-
tion. Previous studies of VDD have largely concentrated upon 
patients recruited within ICU. The prevalence and clinical sig-
nificance in terms of outcomes of VDD in hospitalized mild 
sepsis outside the ICU is unknown.
Our aim was to determine the prevalence and severity of 
VDD in a cohort of sepsis patients both within ICU and in a 
medical admissions unit (MAU) environment as soon as pos-
sible after hospital admission. We used murine sepsis models 
to explore the mechanistic link between preinjurious VDD and 
sepsis. Finally, we undertook studies in intratracheal lipopoly-
saccharide (IT-LPS)-treated VDD mice to demonstrate whether 
rescue therapy with vitamin D can attenuate inflammatory lung 
damage and dysregulated apoptosis associated with VDD (19).
METHODS
Detailed methods are available in the online data supplement 
(Supplemental Digital Content 1, http://links.lww.com/CCM/
C170).
Study Participants
Patients were recruited from the acute MAUs (AMUs) and ICUs 
at two University Hospitals (Heart of England NHS Founda-
tion Trust and the University Hospital Birmingham NHS Foun-
dation Trust) between September 2012 and October 2014 as 
part of an observational sepsis study. Healthy elderly volunteers 
were recruited from a registry at the University of Birmingham 
and provided a cohort of healthy elderly individuals that would 
act as age-matched controls for the sepsis patients.
Ethical Approvals
All patients and healthy volunteers provided informed writ-
ten consent. In circumstances where patients were unable 
to provide consent, a legal representative (personal or des-
ignated consultee) provided assent. Retrospective consent 
was sought where possible, when patients regained the abil-
ity to consent. This study received the appropriate ethical 
 committee and local governance approvals (research ethics 
committee 11/YH0270).
Inclusion Criteria
Age greater than 18 years; documented new proven or sus-
pected infection, and the presence of any two of the signs and 
symptoms of infection (WCC, > 11 or < 4 × 109/L; temperature, 
> 38°C or < 36°C; heart rate, > 90 per beats/min; or respira-
tory rate, > 20 per minute) for less than 24 hours. Patients were 
categorized as sepsis or severe sepsis, according to the presence 
of one or more organ failure at admission (20).
Exclusion Criteria
Recent chemotherapy, chronic steroid use, or use of other 
immunosuppressant drugs.
Laboratory Methods
25(OH)D
3
 was measured by tandem mass spectrometry. The 
assay is calibrated using National Institute of Standards and 
Technology aligned material, achieving certification within 
Vitamin D External Quality Assessment Scheme, and described 
in detail previously (21). 25(OH)D
3
 concentrations below 
50 nmol/L (20 ng/mL) were regarded as deficient. 25(OH)D
3
 
concentrations between 50 and 75 nmol/L (30 ng/mL) were 
regarded as insufficient, with concentrations above 75 nmol/L 
(30 ng/mL) designated sufficient (22).
Animal Materials and Methods
Induction of VDD. Male wild-type (WT) C57Bl/6 mice once 
weaned were made VDD by feeding them a VDD chow (TD 
89123: Harlan, Madison, WI) or maintained on normal chow 
for 6 weeks as a control.
Murine Models of Sepsis and Lung Injury. Cecal ligation 
and puncture (CLP) and intratracheal instillation of LPS were 
performed as described previously (23) and in the online 
data supplement (Supplemental Digital Content 1, http://
links.lww.com/CCM/C170). Cell counts, protein permeabil-
ity index (PPI), quantitative bacterial culture, cathelicidin-
related antimicrobial peptide (CRAMP) levels in peritoneal 
lavage fluid (PLF), blood and bronchoalveolar lavage fluid 
(BALF), and peritoneal macrophage phagocytosis were com-
pared between VDD and VDS mice in the CLP model. BALF 
cell counts, PPI, receptor for advanced glycation end-prod-
ucts (RAGE), and oxygen saturations were compared in the 
IT-LPS model.
Statistics
Initial power calculations for eight animals in each arm for the 
CLP experiment were based upon preliminary data to detect a 
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change in lung PPI of 20% between VDD and VDS mice and 
six animals per arm to see a treatment effect on BALF neu-
trophils of 15% in the IT-LPS experiment. CLP experiments 
were performed in batches of four mice at different time 
points. Uneven numbers account for a failure in the experi-
ment. Data were analyzed using SPSS for Windows 16.0 (SPSS, 
Chicago, IL). Data were tested for normality using a Shapiro-
Wilks test with parametric data analyzed using unpaired t tests 
and a Mann-Whitney U test for nonparametric data. Data 
are expressed as mean (sd) unless otherwise indicated. A chi-
square or Fisher exact test was used to compare proportions. A 
two-tailed p value of less than 0.05 was considered significant.
RESULTS
Patient Cohorts
Sepsis Patients. We enrolled 61 patients with sepsis—20 had 
mild sepsis and 41 had severe sepsis. Twelve patients were 
enrolled in the ICU and 49 were enrolled in AMUs. Two 
patients were transferred from AMUs to ICU postrecruitment. 
The etiology of sepsis was predominantly community-acquired 
pneumonia with a similar range of causes between sepsis and 
severe sepsis. As expected severity scores Acute Physiology and 
Chronic Health Evaluation (APACHE) II and SOFA score were 
significantly greater in severe sepsis than mild sepsis (Table 1)
TAbLE 1. Demographics and Severity of Patient Cohorts/Volunteers
Category
Healthy  
(n = 20)
Sepsis  
(n = 20)
Severe Sepsis  
(n = 41)
Age, yr (sd) 65.5 (8.2) 66.5 (21.4) 66.4 (17.8)
Sex, male:female 10:10a 14:6 25:16
25-hydroxyvitamin D3 (nmol/L) 66.5 (38.9–79.1) 49.5 (34.8–61.8) 15.7b (9.8–31.1)
Etiology, n (%)
 Community-acquired pneumonia — 14 (70) 28 (68)
 Urosepsis — 3 (15) 4 (10)
 Abdominal — 1 (5) 2 (5)
 Skin — 1 (5) 5 (12)
 Neurologic — 1 (5) 0
 Other — 0 2 (5)
Comorbidities, n
 None 20 5 7
 Cardiovascular 0 9 25
 Respiratory 0 7 14
 Chronic renal disease 0 0 2
 Diabetes 0 3 8
Acute Physiology and Chronic Health Evaluation II (IQR) — 11 (8–15) 17.5 (14–19.8)c
Sequential Organ Failure Assessment score (IQR) — 1 (0–1.1) 4 (2–6.5)d
ICU admission &, n — 2 12
 Inotropes — 0 4
 Ventilatory support — 0 2
 Multiple organ support — 0 8
30-d mortality, n (%) 0/20 4/20 (20) 7/41 (17)
90-d mortality, n (%) 0/20 6/20 (30) 9/41 (22)
365-d mortality, n (%) 0/20 10/20 (50) 15/41 (36)
IQR	=	interquartile	range.
ap	=	not	significant	between	healthy	and	sepsis/severe	sepsis.
bp	=	0.0001	severe	sepsis	vs	sepsis	and	healthy	controls,	with	nonsignificant	difference	between	sepsis	and	healthy	controls.
cp	=	0.0014	sepsis	vs	severe	sepsis.
dp	=	0.0001	sepsis	vs	severe	sepsis.
Thirty-day	mortality	p	=	0.59	sepsis	vs	severe	sepsis,	90	day	p	=	0.44.	A	total	of	365	d	p	=	0.4	and	ICU	admission	at	any	point	during	hospital	stay.
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Healthy Donors. Blood from 20 healthy elderly donors were 
obtained—volunteers had no evidence of significant acute or 
chronic disease, normal spirometry, and were medication free. 
There were no significant differences in age or sex distribution 
between the healthy cohort, sepsis patients, and severe sepsis 
patients (Table 1).
25(OH)D3 Concentrations Are Lower in Patients With 
Severe Sepsis Compared With Sepsis and Healthy 
Controls
Of 61 patients, 41 met the criteria for severe sepsis with 14 requir-
ing critical care at some point during their admission. Patients with 
severe sepsis had significantly lower 25(OH)D
3
 concentrations 
than either sepsis patients or con-
trols (15.7 vs 49.5 vs 66.5 nmol/L; 
p = 0.0001). In contrast, patients 
with sepsis did not have signifi-
cantly lower concentrations of 
25(OH)D
3
 than healthy controls 
(Table 1) (online supplement 
Fig. 1, Supplemental Digital 
Content 1, http://links.lww.com/
CCM/C170).
25(OH)D3 Concentrations 
Are Lower in Sepsis 
Patients With Positive 
Microbial Cultures
Twenty-two patients (36%) 
had positive cultures (blood/
urine/sputum/BALF) for bac-
terial growth from samples 
taken as part of their clini-
cal workup. Median 25(OH)
D
3
 concentrations were sig-
nificantly lower in patients 
who were culture positive 
(16.5 nmol/L) compared with 
culture negative patients (35.5 
nmol/L; p = 0.0023) (online 
supplement Fig. 2, Supplemen-
tal Digital Content 1, http://
links.lww.com/CCM/C170).
There was an inverse rela-
tionship between 25(OH)D
3
 
at baseline and standardized 
base excess and blood lactate 
(mmol/L) (Fig. 1, A and B). 
There was no relationship 
between 25(OH)D
3
 and age, 
sex, ethnicity, or the sever-
ity scores Sequential Organ 
Failure Assessment (SOFA) or 
APACHE II (data not shown).
25(OH)D3 Concentrations 
Are Lower in Patients Who 
Die Within 30 Days of 
Admission Than Survivors
Previous studies have suggested 
25(OH)D
3
 concentrations are 
associated with mortality in 
ICU patients. In our whole 
Figure 1. Regression plots for plasma 25-hydroxyvitamin D3 (25[OH]D3) and A, standardized base excess 
and b, blood lactate at admission. Regression was performed using Spearman’s rho for nonparametric data. 
C, Plasma 25(OH)D3 between survivors and nonsurvivors at 30 d, 90 d, and 1 yr. Box and whisker plots with 
median and Tukey’s distribution.
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cohort, there was a significant difference in median 25(OH)D
3
 
concentrations between survivors (25.9 nmol/L) and nonsur-
vivors (14.5 nmol/L; p = 0.025) at 30 (11/61) days. This effect 
was not significant for 90-day mortality (15/61) or 1-year mor-
tality (25/61) (Fig. 1C)
Severe VDD Is Associated With Increased Risk of 
Death in Patients With Sepsis
We have previously reported increased adverse postopera-
tive inflammation and adverse events in patients undergoing 
esophagectomy who had severe deficiency before the operation 
(25[OH]D
3
, < 20 nmol/L) (19). In line with these data, sepsis 
patients with 25(OH)D
3
 concentrations below 20 nmol/L had 
a significant increased risk of 30-day mortality. Fisher exact 
test was significant at p value equal to 0.02 giving a relative risk 
of 4.71 (95% CI, 1.089–20.42).
MURINE STUDIES
Murine Vitamin D Status
VDD was successfully established in WT C57BL/6 mice fed a 
deficient diet compared with a VDS diet (online supplement 
Table 1, Supplemental Digital Content 1, http://links.lww.
com/CCM/C170). 25(OH)D
3
 concentrations in the mice were 
equivalent to those seen in patients who died from severe sep-
sis. Deficiency did not result in a significant effect on serum 
calcium but was associated within reduced circulating bioac-
tive 1,25(OH)
2
D
3
.
VDD Is Associated With Increased Peritoneal/
Systemic bacteremia and Alveolar bacterial 
Translocation After CLP
VDD mice had a significantly higher bacterial load compared 
with VDS mice in all three compartments (peritoneal, blood, 
and alveolar) 16 hours after CLP (Fig. 2A). In sham experi-
ments, there was an absence of bacteria as measured by colony 
forming units per milliliter in all three compartments confirm-
ing sterile procedure and surgery (data not shown).
CRAMP Is Reduced in VDD Mice
CRAMP has been widely identified as a vitamin D-dependent 
antimicrobial peptide that binds bacteria. Cathelicidin rapidly 
destroys the lipoprotein membranes of microbes enveloped in 
phagosomes after fusion with lysosomes in macrophages (24).
The CLP procedure increases CRAMP concentrations sig-
nificantly in PLF, serum, and BALF in VDS mice. However, 
significantly lower concentrations were observed in VDD mice 
supporting the observation that VDD mice have reduced anti-
microbial capacity (Fig. 2, B–D).
CLP Does not Induce Alveolar Neutrophilia but Does 
Increase PPI, Which Is More Pronounced in VDD
Little-to-no cellular recruitment into the alveolar compart-
ment was observed at this time point; however, there was 
evidence of a mild increase in BALF PPI, suggesting early 
alveolar epithelial leak. This was significantly higher in VDD 
mice when compared with VDS mice (median, 3.30 [inter-
quartile range (IQR), 2.69–
4.64] vs 2.09 [IQR, 1.82–2.90]; 
p = 0.014) (online supplement 
Fig. 3, Supplemental Digital 
Content 1, http://links.lww.
com/CCM/C170).
VDD Is Associated 
With Increased Cellular 
Inflammation in the 
Peritoneum
After CLP there was signifi-
cant cellular recruitment in 
PLF. As major players of the 
acute inflammatory response, 
neutrophils and F4/80+ mac-
rophages were enumerated 
within the peritoneal cavity. 
Significantly more neutrophils 
and F4/80+ macrophages were 
observed in VDD compared 
with VDS mice after CLP, with 
the neutrophil-to-macrophage 
ratio similar between both 
groups indicating a global 
increase in inflammatory 
mediators. PLF PPI was also 
significantly increased in VDD 
Figure 2. A, Effect of vitamin D deficient (VDD) on bacterial load in peritoneal lavage fluid (PLF), blood, 
and bronchoalveolar lavage fluid (BALF). Data presented as box and whisker plots with median and Tukey’s 
distribution, logarithmic scale to allow graphical representation. VDD n = 12; vitamin D sufficient (VDS) n = 11. 
Cathelicidin-related antimicrobial peptide (CRAMP) (murine cathelicidin) expression in b, PLF; C, serum; and D, 
BALF. Box and whisker plots with medians and Tukey’s distribution. VDD n = 12; VDS n = 11. Sham n = 4 per 
group. CRAMP was undetectable in sham-treated sera. CFU = colony forming units, CLP = cecal ligation and 
puncture, NS = not significant.
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mice (median, 46.86 [IQR, 28.17–58.33] vs 29.81 [14.81–
54.52]; p = 0.06) also indicative of more vascular damage in 
VDD mice after CLP (online supplement Fig. 4, Supplemental 
Digital Content 1, http://links.lww.com/CCM/C170).
VDD Is Associated With Dysregulated Neutrophil 
Apoptosis and Impaired Peritoneal Macrophage 
Phagocytosis of bacteria After CLP
There was a significant increase in the number of apoptotic neu-
trophils in VDD compared with VDS PLF (median, 1.87 × 105 
[IQR, 0.89–4.19 × 105] vs 0.51 × 105 [IQR, 0.20–0.54 × 105]; 
p = 0.007) (Fig. 3A), suggesting dysregulated neutrophil apop-
tosis and clearance of dying cells. To determine whether the 
increased bacteremia and/or accumulation of apoptotic neu-
trophils observed in VDD mice was due to impaired clearance 
by peritoneal macrophages, we assessed bacterial phagocytosis 
after CLP. Ex vivo phagocytosis of pHrodo-labeled Escherichia 
coliform bacteria was significantly reduced in F4/80+ macro-
phages isolated from PLF of VDD compared with VDS mice 
after CLP (median, 6.89% [IQR, 3.12–9.87] vs 21.12% [IQR, 
17.56–24.29]; p = 0.029) (Fig. 3B).
Intraperitoneal (IP) Liquid Cholecalciferol (Vigantol) 
Rescue Therapy Attenuates Vitamin D-Related 
Inflammatory Damage Even When Given 6 Hours 
After IT-LPS Challenge
In the United Kingdom, we can only use the CLP model of early 
sepsis due to home office animal license rules. To assess whether 
rescue therapy with vitamin D was effective postinjury, we stud-
ied our well-characterized IT-LPS challenge model, which we 
have previously reported results in exaggerated inflammation in 
VDD mice (23). Animals were administered 1,500 IU (75 µL) 
of cholecalciferol (Vigantol; Merck Serono GmbH, Darmstadt, 
Germany) or phosphate buffered saline control IP injection 6 
hours postinjury and killed after 48 hours.
Vigantol administration restored 25(OH)D
3
 concentrations 
in VDD mice to those similar to WT, which was sufficient to 
normalize the lung injury post- IT-LPS (online supplemental 
Fig. 5, Supplemental Digital Content 1, http://links.lww.com/
CCM/C170). Vigantol treatment 6 hours post-IT-LPS reduced 
BALF PPI, RAGE (a marker of alveolar epithelial damage), and 
normalized BALF neutrophil apoptosis (Fig. 4, A–C). In addi-
tion, Vigantol attenuated the exaggerated decrease in oxygen 
saturations seen in this model with VDD mice (Fig. 4D).
DISCUSSION
We have confirmed, in a cohort of hospitalized patients with 
sepsis, that VDD is common, severe, and is associated with dis-
ease severity, bacterial positive culture, and 30-day mortality. To 
demonstrate causation of VDD as a driver of sepsis severity, our 
CLP mouse studies demonstrated exaggerated bacterial growth 
both locally and systemically, increased cellular inflammation, 
and dysregulated accumulation of apoptotic neutrophils in 
VDD mice. Using the IT-LPS challenge model, we demonstrate 
that the novel administration of IP cholecalciferol is an effective 
postinjury therapy when given 6 hours postinjury.
We enrolled a mixed population of both mild and severe 
sepsis patients. VDD was both common and severe in patients 
with severe sepsis. 25(OH)D
3
 concentrations were lower in 
patients who died than survived as well as patients who grew 
culture positive bacterial specimens. Additionally, clinical 
markers of sepsis severity (lactate, metabolic acidosis) were 
associated with lower levels of 25(OH)D
3
 suggesting perhaps 
these measures could reflect a VDD population in sepsis. A 
criticism often levelled at observational studies, such as ours, is 
whether the VDD is a marker of critical illness or a mechanistic 
driver. Two recent meta-analyses of observational studies have 
confirmed a significant association between vitamin D status 
and susceptibility to sepsis (18), rates of infection, and 30-day 
mortality (17). Our findings are concordant with observational 
studies that have demonstrated that low vitamin D status upon 
admission is associated with sepsis (16), bacteremia (25), and 
acute respiratory distress syndrome (26, 27).
The murine studies sought to establish whether inducing 
VDD by diet before injury in mice leads to exaggerated sepsis and 
enhanced cellular inflammation/
dysfunction. We successfully 
established severe deficiency in 
the mice, with concentrations of 
25(OH)D
3
 similar to those who 
died from sepsis in our clini-
cal cohort. This deficiency was 
reflected also in reduced circulat-
ing 1,25(OH)
2
D
3
, the bioactive 
form of vitamin D. In contrast, 
our WT mice had 25(OH)D
3
 
and 1,25 (OH)
2
D
3
 concentra-
tions similar to our mild sepsis 
patient population.
In the clinically relevant 
CLP model of early sepsis, 
VDD was associated with 
exaggerated bacterial growth 
Figure 3. A, Peritoneal lavage fluid (PLF) neutrophil apoptosis. Box and whisker plot with median and 
Tukey’s distribution, vitamin D deficient (VDD) n = 12; vitamin D sufficient (VDS) n = 11. b, PLF macrophage 
phagocytosis of pHrodo-labeled E. coli bacteria. Box and whisker plot with median and Tukey’s distribution, 
Mann-Whitney test. VDD n = 4; VDS n = 4.
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in the peritoneal cavity, elevated systemic bacteremia as well 
as increased bacterial translocation to the alveolar compart-
ment. This was associated with abnormal protein permeabil-
ity of the peritoneal and alveolar capillary barrier. In the PLF, 
there was exaggerated cellular inflammation in VDD mice 
with evidence of impaired antibacterial responses in terms 
of CRAMP release and the ability of peritoneal macrophages 
to phagocytose E. coli. These cellular changes resulted in 
increased accumulation of apoptotic neutrophils in the PLF. 
Previous animal studies have shown a benefit of 1,25(OH)
2
D
3
 
on sepsis-induced coagulopathy in rats (28) and our CRAMP 
results confirm findings by others of decreased antimicro-
bial peptide in VDD in sepsis and critical illness (29, 30). 
Our study is the first to report VDD as a predeterminant of 
sepsis and decreased macro-
phage phagocytosis in a rel-
evant murine model. These 
data support our hypothesis 
that VDD is mechanistically 
important in driving sepsis 
and led us to the question of 
whether treating deficiency 
postinjury would be an effec-
tive therapy.
In the United Kingdom, 
the regulatory framework for 
animal experiments dictated 
that we could not keep VDD 
animals alive post-CLP for 
more than 16 hours because 
of serious adverse events so 
we were only able to model 
early sepsis using this tech-
nique. Our group has recently 
shown a detrimental effect of 
VDD with exaggerated lung 
injury, dysregulated cellular 
inflammation, and apoptosis, 
which manifested as reduced 
oxygenation in an IT-LPS 
direct murine lung injury 
model 48 hours after injury 
(19). We, therefore, used our 
IT-LPS model to test whether 
postinjury treatment of VDD 
mice attenuated the effects 
of VDD upon inflammatory 
injury.
Traditionally, vitamin D 
supplements have been given 
by mouth, intramuscular 
injection (cholecalciferol and 
ergocalciferol), or by IV infu-
sion (calcitriol) with mixed 
results potentially due to poor 
absorption from muscle or 
the gut or a short IV half-life (31–33). We elected to test the 
effect of IP administration of 1,500 IU cholecalciferol liquid 
as a novel route to restore VDS—a dose that proved effective 
in restoring 25(OH)D
3
 concentrations back to those seen 
in WT mice. Postinjury cholecalciferol therapy was effective 
in reducing the exaggerated cellular inflammation, alveolar 
epithelial damage as measured by PPI and RAGE release, 
and reduced hypoxia (oxygen saturations) when given 6 
hours after the insult supporting IP administration of cho-
lecalciferol as a novel potential route of administration in 
patients as well as evidence that restoration of vitamin D 
levels may reduce inflammation with physiologic benefit.
This study has limitations. First, patients were recruited up 
to 48 hours after hospital admission, so it is possible that the 
Figure 4. Effect of intraperitoneal liquid cholecalciferol (Vigantol) rescue therapy upon (A) bronchoalveolar 
lavage fluid protein permeability index (BAL PPI); b, BAL receptor for advanced glycation end-products 
(BAL RAGE); C, BALF total apoptotic cell count, and D, arterial oxygen saturation in wild-type (WT) vitamin D 
sufficient mice given intratracheal lipopolysaccharide (IT-LPS), vitamin D deficient (VDD) mice given IT-LPS, and 
VDD mice given IT-LPS and 1,500 IU unit rescue therapy with cholecalciferol (postVIG) 6 hr postinjury. Mice 
were killed at 48 hr post-IT-LPS (n = 6 per arm).
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25(OH)D
3
 concentrations seen reflected changes associated with 
sepsis rather than the cause. Second, this is a retrospective study 
of a small number of patients that could not control for patient 
comorbidities. The effects of sepsis and critical illness on the 
vitamin D metabolome are unknown and this complex interplay 
needs prospective large-scale studies that consider other prein-
sult comorbidities, chronic illness, nutritional status, and other 
confounders. It was for this reason we did the murine studies. In 
our CLP model, we studied early sepsis due to restrictions from 
the animal ethics committee. This meant that our animals had 
limited alveolar damage, which was why we undertook addi-
tional studies in the IT-LPS model. Although the VDD induced 
by diet design investigated whether pre-existing VDD is causal 
and a mechanistic driver to the severity of sepsis rather than the 
consequence of the sepsis insult in the murine model, it may not 
wholly explain the findings of the human study due to the lack 
of vitamin D status before sepsis and its effects on vitamin D 
status as discussed above. Finally, we have shown the effects of 
VDD in only two models of murine lung injury. Further work in 
other models related to sepsis particularly experimental pneu-
monia need to be undertaken.
In conclusion, we suggest that therapies aimed at restoring 
VDS in patients at risk of deficiency when they are admitted to 
hospital need to be developed to try and prevent the increasing 
healthcare burden of sepsis patients. Key to this will be estab-
lishing appropriate dosing regimens for vitamin D replacement 
in the critically ill patients both within and outside the ICU.
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